Skip to main content
. 2023 Apr 16;12(11):12325–12335. doi: 10.1002/cam4.5931

FIGURE 2.

FIGURE 2

Overall survival duration in patients with HCC treated with Atez/Bev according to treatment response by RECIST. The black, dotted, and thin line indicates the PR, SD, and PD group, respectively. Atez/Bev, atezolizumab plus bevacizumab; CR, complete response; HCC, hepatocellular carcinoma; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease.